Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Generex Biotechnology (NasdaqNM:GNBT)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Location
33 Harbor Square, Suite 202, Ontario
Toronto, M5J 2G2, Canada
Phone: (416) 364-2551
Fax: (416) 364-9363
Email: info@generex.com
Employees (last reported count): 25
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 47%
·Institutional: 8% (15% of float)
(14 institutions)
·Net Inst. Selling: 89.0K shares (+6.25%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Generex Biotechnology is engaged in the research and development of drug delivery systems and technology. The Company is a development stage company. To date, the Company has devoted a substantial majority of its efforts and resources in developing a technology to orally administer large molecule drugs, including proteins, hormones, peptides, vaccines and other pharmaceutical products. The initial application of the Company's large molecule drug delivery technology is an oral insulin formulation for use in the treatment of diabetes. The formulation is sprayed into the mouth using a hand-held aerosol applicator.
More from Market Guide: Expanded Business Description

Financial Summary
Generex Biotechnology is primarily engaged in the development of a proprietary drug delivery platform technology to orally administer large molecule drugs which, historically, have been administered by injection. For the nine months ended 4/30/01, revenues totaled $1 million, up from $0. Net loss totaled $18.1 million, up from $6.3 million. Results reflect $1 million received in connection with the Eli Lilly agreement, offset by increased research and development expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

E. Mark Perri, 39
Chairman, CFO
$103K
Anna Gluskin, 49
Pres, CEO
105K
Rose Perri, 33
COO, Sec., Treasurer
97K
Pankaj Modi, Ph.D., 46
VP of R&D
--  
Dollar amounts are as of 31-July-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GNBTAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$4.25 
Recent Price$7.80 
52-Week High
on 6-Sep-2000
$24.875
Beta1.51 
Daily Volume (3-month avg)173.0K
Daily Volume (10-day avg)63.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-59.2%
52-Week Change
relative to S&P500
-45.3%
Share-Related Items
Market Capitalization$150.5M
Shares Outstanding19.3M
Float10.2M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.83 
Earnings (ttm)-$1.12 
Earnings (mrq)-$0.14 
Sales (ttm)$0.06 
Cash (mrq)$1.49 
Valuation Ratios
Price/Book (mrq)4.26 
Price/EarningsN/A 
Price/Sales (ttm)139.01 
Income Statements
Sales (ttm)$1.00M
EBITDA (ttm)-$24.6M
Income available to common (ttm)-$20.6M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJuly 31
Most recent quarter30-Apr-2001
Management Effectiveness
Return on Assets (ttm)-79.46%
Return on Equity (ttm)-85.65%
Financial Strength
Current Ratio (mrq)36.05 
Debt/Equity (mrq)0.02 
Total Cash (mrq)$28.8M
Short Interest
As of 8-Aug-2001
Shares Short735.0K
Percent of Float7.2%
Shares Short
(Prior Month)
954.0K
Short Ratio8.45 
Daily Volume87.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-Apr-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.